Single Arm Phase II, Multicenter Study of Concomitant Radiotherapy, Tremelimumab and Durvalumab (MEDI4736) for Metastatic or Locally Advanced NSCLC Patients Progressing on First-line Immunotherapy
Latest Information Update: 14 Jan 2022
At a glance
- Drugs Durvalumab (Primary) ; Docetaxel; Tremelimumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CORAL-Lung
- 09 Jan 2022 Status changed from not yet recruiting to recruiting.
- 10 Nov 2021 Planned End Date changed from 1 Sep 2026 to 1 Dec 2026.
- 10 Nov 2021 Planned primary completion date changed from 1 Sep 2026 to 1 Dec 2026.